Wes Streeting Proposes Capital Gains Tax Reforms as Part of Labour Leadership Pitch Indias Gherkin Exports Reach Record 307 Million in FY26 Despite US Tariffs MidAmerica Apartment Communities Faces Subpar Rent Outlook After Scotiabank Downgrade Sebi Proposes Standardised Options Strike Price Norms to Address Intraday Volatility Trump Seeks Supreme Court Intervention to Delay TikTok Ban Vestas Wind Systems Shares Slide After Company Warns Margins Could Reach Lower End of Forecast Range CHD Q1 2026 Earnings EPS Beat Fails to Lift Stock Amid Mixed Signals Skye Bioscience Q1 2026 Earnings WiderthanExpected Loss Highlights PreRevenue Biotech Challenges PNC Q1 2026 Earnings EPS Beat Amid Modest Stock Reaction MTRN Q1 2026 Earnings EPS Surpasses Estimates by 64 Stock Rises Modestly ADAMZ Q1 2026 Earnings Preferred Stock Delivers Strong EPS Beat Despite Modest Share Decline GBank Financial Holdings Inc GBFH Q1 2026 Earnings Significant EPS Miss as Earnings Fall Short of Expectations Catheter Precision VTAK Narrows Trading Range With Modest Decline of 011 as Key Support Holds Unicycive Therapeutics UNCY Edges Higher as Stock Tests Key Resistance Near 746 Pulmonx LUNG Sees Modest Decline Amid Key Support Test SkyWater Technology SKYT Edges Higher as Semiconductor Foundry Stock Tests Key Resistance Sanofi ADS SNY Edges Higher Consolidation Within Established Range RCI Hospitality Holdings RICK Slips Slightly as Traders Weigh Support and Resistance Levels Werner Enterprises WERN Edges Higher as Trucking Sector Stabilizes Key Support and Resistance Levels in View Quantum Biopharma Ltd QNTM Surges 18 Key Levels and Potential Drivers Mesa Royalty Trust MTR Advances 131 as Price Approaches Key Resistance at 405 Ekso Bionics EKSO Gains Ground as Shares Approach Key Resistance Myomo Inc MYO Surges 95 as Medical Device Penny Stock Breaks Above Key Support Citi Lifts Price Target on Marvell Technology Highlighting Potential Upside for Chipmaker Amphastar Pharmaceuticals AMPH Q1 2026 Earnings EPS Misses Estimates by Over 40 Yet Stock Rises ProQR Therapeutics PRQR Holds Steady Near 157 as Uplift Potential Remains